Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Delcath Systems Inc (NASDAQ:DCTH)

0.096
Delayed Data
As of 3:59pm ET
 -0.006 / -5.88%
Today’s Change
0.08
Today|||52-Week Range
6.85
-89.57%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$4.1M

Company Description

Delcath Systems, Inc. is a pharmaceutical and medical device company, which focuses on oncology and liver cancer therapy. It develops and commercializes Melphalan Hydrochloride for Injection, which is a proprietary product for use with the Delcath Hepatic Delivery System. It is designed to administer concentrated regional chemotherapy to the liver. The company was founded on August 5, 1988 and is headquartered in New York, NY.

Contact Information

Delcath Systems, Inc.
1633 Broadway
New York New York 10019
P:(212) 489-2100
Investor Relations:

Employees

Shareholders

Other institutional0.93%
Individual stakeholders0.25%
Mutual fund holders0.15%

Top Executives

Jennifer K. SimpsonPresident, Chief Executive Officer & Director
John PurpuraExecutive Vice President-Global Operations
Barbra C. KeckSecretary, Chief Financial & Accounting Officer
Jason A. RifkinVice President-Commercial Programs